echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Eli Lilly's IL-2R agonist application for clinical application

    Eli Lilly's IL-2R agonist application for clinical application

    • Last Update: 2021-05-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, the official website of CDE showed that the clinical application of Eli Lilly IL-2R agonist LY3471851 injection (NKTR-358) was officially accepted by the State Food and Drug Administration.


    IL-2 production disorder and regulatory T cell (Treg) dysfunction are thought to be related to the occurrence of a variety of autoimmune diseases.


    NKTR-358 is a First-in-Class IL-2R agonist developed by Nektar Company.


    Preclinical studies have shown that NKTR-358 has low affinity for IL-2Rβγ and high affinity for IL-2Rαβγ, and can selectively restore Treg levels without affecting the function of traditional T cells (Tcon).


    Experimental results of non-human primate animal models show that Treg cells can be selectively expanded

    Experimental results of non-human primate animal models show that Treg cells can be selectively expanded

    In June 2020, Eli Lilly and Nektar jointly announced the phase Ib clinical study data of NKTR-358 for patients with moderate to severe systemic lupus erythematosus (SLE).


    The results of the study showed that the safety of NKTR-358 was well tolerated, and the Treg cells in patients showed a significant, selective and dose-dependent increase, and they were maintained after multiple administrations.


    The increase of Tregs in SLE patients in the NKTR-358 24μg/kg dose group was similar to the increase observed in the 28μg/kg dose group in healthy volunteers.


    And NKTR-358 did not cause changes in the levels of traditional T cells and NK cells in patients as a whole.


    After multiple administrations, the level of Tregs in SLE patients was similar to that of healthy volunteers.


    Eli Lilly is currently carrying out a phase II clinical study of NKTR-358 for the treatment of SLE, and two other phase Ib studies for psoriasis and atopic dermatitis are also underway.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.